Dyve Biosciences

Dyve Biosciences is a drug development company using proprietary science to create novel therapeutics. The company is rapidly developing a strong pipeline across a broad range of therapeutic areas based around its proprietary science. Dyve's most advanced asset, DYV-700, is in Phase 2 for the treatment of acute gout using a first-in-class mechanism of action enabled by Dyve's science. The company has PK data demonstrating injection-like delivery across a diverse set of molecules.